We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Development of a quantitative COVID-19 multiplex assay and its use for serological surveillance in a low SARS-CoV-2 incidence community.
- Authors
Guarino, Cassandra; Larson, Elisabeth; Babasyan, Susanna; Rollins, Alicia; Joshi, Lok R.; Laverack, Melissa; Parrilla, Lara; Plocharczyk, Elizabeth; Diel, Diego G.; Wagner, Bettina
- Abstract
A serological COVID-19 Multiplex Assay was developed and validated using serum samples from convalescent patients and those collected prior to the 2020 pandemic. After initial testing of multiple potential antigens, the SARS-CoV-2 nucleocapsid protein (NP) and receptor-binding domain (RBD) of the spike protein were selected for the human COVID-19 Multiplex Assay. A comparison of synthesized and mammalian expressed RBD proteins revealed clear advantages of mammalian expression. Antibodies directed against NP strongly correlated with SARS-CoV-2 virus neutralization assay titers (rsp = 0.726), while anti-RBD correlation was moderate (rsp = 0.436). Pan-Ig, IgG, IgA, and IgM against NP and RBD antigens were evaluated on the validation sample sets. Detection of NP and RBD specific IgG and IgA had outstanding performance (AUC > 0.90) for distinguishing patients from controls, but the dynamic range of the IgG assay was substantially greater. The COVID-19 Multiplex Assay was utilized to identify seroprevalence to SARS-CoV-2 in people living in a low-incidence community in Ithaca, NY. Samples were taken from a cohort of healthy volunteers (n = 332) in early June 2020. Only two volunteers had a positive result on a COVID-19 PCR test performed prior to serum sampling. Serological testing revealed an exposure rate of at least 1.2% (NP) or as high as 5.7% (RBD), higher than the measured incidence rate of 0.16% in the county at that time. This highly sensitive and quantitative assay can be used for monitoring community exposure rates and duration of immune response following both infection and vaccination.
- Subjects
NEW York (N.Y.); ITHACA (N.Y.); SARS-CoV-2; COVID-19; COVID-19 pandemic; VIRAL antibodies; POLYMERASE chain reaction; SERODIAGNOSIS; IMMUNOGLOBULINS; IMMUNOGLOBULIN M
- Publication
PLoS ONE, 2022, Vol 17, Issue 1, p1
- ISSN
1932-6203
- Publication type
Article
- DOI
10.1371/journal.pone.0262868